Works by Zeng, Xiaohua


Results: 63
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-56096-2
    By:
    • Xu, Binghe;
    • Zhang, Qingyuan;
    • Luo, Yang;
    • Tong, Zhongsheng;
    • Sun, Tao;
    • Shan, Changping;
    • Liu, Xinlan;
    • Yao, Yumin;
    • Zhao, Bing;
    • Wang, Shusen;
    • Zeng, Xiaohua;
    • Hu, Changlu;
    • Yan, Xi;
    • Wang, Xiaojia;
    • Jia, Hongyan;
    • Chen, Zhendong;
    • Qiu, Fuming;
    • Wu, Xinhong;
    • Zhang, Deyong;
    • Li, Tong
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 15, p. 1, doi. 10.1002/cam4.7408
    By:
    • Shao, Zhimin;
    • Tong, Zhongsheng;
    • Liu, Qiang;
    • Li, Wei;
    • Cai, Li;
    • Shen, Kunwei;
    • Li, Huiping;
    • Wang, Chuan;
    • Yang, Jin;
    • Song, Zhenchuan;
    • Wang, Shui;
    • Luo, Ting;
    • Zhao, Wenhe;
    • Wang, Haibo;
    • Pan, Yueyin;
    • Nie, Jianyun;
    • Zeng, Xiaohua;
    • Bai, Yanqing;
    • Chiang, Wendy;
    • Guarnaccia, Valeria
    Publication type:
    Article
    36
    37
    38

    A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.

    Published in:
    Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221122715
    By:
    • Yan, Min;
    • Yuan, Peng;
    • Ouyang, Quchang;
    • Cheng, Ying;
    • Han, Guohui;
    • Wang, Dewei;
    • Ran, Li;
    • Sun, Tao;
    • Zhao, Da;
    • Bai, Yuju;
    • Yang, Shun'e;
    • Wang, Xiaojia;
    • Wu, Rong;
    • Zeng, Xiaohua;
    • Yao, Herui;
    • Ji, Xuening;
    • Jiang, Jun;
    • Hu, Xiaohua;
    • Lin, Haifeng;
    • Zheng, Liping
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments.

    Published in:
    International Journal of Cancer, 2023, v. 152, n. 10, p. 2134, doi. 10.1002/ijc.34424
    By:
    • Xu, Binghe;
    • Ma, Fei;
    • Wang, Tao;
    • Wang, Shusen;
    • Tong, Zhongsheng;
    • Li, Wei;
    • Wu, Xinhong;
    • Wang, Xiaojia;
    • Sun, Tao;
    • Pan, Yueyin;
    • Yao, Herui;
    • Wang, Xian;
    • Luo, Ting;
    • Yang, Jin;
    • Zeng, Xiaohua;
    • Zhao, Weihong;
    • Cong, Xiuyu Julie;
    • Chen, Jiongjie
    Publication type:
    Article
    50